Multisystem inflammatory syndrome in a young adult successfully treated with plasmapheresis, immunoglobulins, and corticosteroids: a case report

Int J Infect Dis. 2022 Sep;122:1052-1055. doi: 10.1016/j.ijid.2022.07.059. Epub 2022 Jul 28.

Abstract

A novel condition named multisystem inflammatory syndrome has raised the alarm worldwide and is leading to severe illness and long-term effects in the post-COVID era. This condition includes infection with fever, abdominal symptoms, acute cardiac injury, and shock. It has similarities with severe forms of Kawasaki disease (KD). In this study, we present a case of a 20-year-old male patient with multisystem inflammatory syndrome associated with COVID-19 infection who was successfully treated with plasmapheresis, immunoglobulins, and steroids for 4 h/day without heparinization or ultrafiltration. Plasmapheresis represents a therapeutic option for KD in patients with all other therapeutic strategies that have failed. However, there is no evidence from controlled clinical trials confirming this option. In our case, plasmapheresis was beneficial in stabilizing and improving the patient's clinical condition. Given the pathophysiological and therapeutic similarities between KD and multisystem inflammatory syndrome, it could be considered a therapeutic option.

Keywords: COVID-19; Multisystem inflammatory syndrome; Plasmapheresis.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • COVID-19* / therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Male
  • Mucocutaneous Lymph Node Syndrome*
  • Plasmapheresis
  • Systemic Inflammatory Response Syndrome / complications
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Immunoglobulins, Intravenous